Marathon Asset Management 13F: Cuts RPRX Stake by $1.4M
Key Points
- Marathon Asset Management trimmed its stake in Royalty Pharma by 24,504 shares, a decrease of 8.57%, as reported in its latest 13F filing.
- Marathon Asset Management held 261,447 $RPRX shares at quarter end, down 8.57% from the prior quarter.
- The fund's remaining holdings in Royalty Pharma are now worth about $15.3 million, representing 1.21% of its total portfolio valued at $1.26 billion.
- Royalty Pharma recently traded around $64.76, just above its recent performance, with next earnings scheduled for November 4, 2026.
Get Royalty Pharma plc text alerts
We text you when insiders, Congress, analysts or big funds move on $RPRX.
By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Royalty Pharma plc alert may contain errors. Disclosures
Marathon Asset Management trimmed its position in Royalty Pharma plc (RPRX) by 24,504 shares, reducing its stake to 261,447 shares valued at approximately $15.3 million. This change was disclosed in a filing on October 26, 2026, and reflects an 8.57% decrease in its holdings.
RPRX
Royalty Pharma plc
Where Royalty Pharma Fits in Marathon Asset Management's Portfolio
The trimmed position now accounts for 1.21% of Marathon's total reported value of $1.26 billion, ranking it 30th among the fund's 76 holdings. This adjustment suggests a strategic shift in how Marathon views its investment in Royalty Pharma.
Other Institutional Activity in Royalty Pharma
Capital International Investors added 269,533 shares to its position, bringing its total to 35,273,770 shares worth about $2.28 billion. Meanwhile, Swedbank AB reduced its stake by 859,704 shares, now holding 10,726,608 shares valued at approximately $694.7 million. BAILLIE GIFFORD & CO also decreased its position by 6,141,185 shares, leaving it with 10,015,578 shares worth around $648.6 million.
Royalty Pharma plc Stock Up 1.6%
Royalty Pharma recently traded around $64.76, reflecting its performance in a competitive biotechnology sector. The stock's position is notable as the company prepares for its upcoming earnings report on November 4, 2026.
Recent Earnings
Royalty Pharma reported trailing twelve-month revenue of about $2.54 billion, with a net margin of 32% and a return on equity of 14%. The company has shown a revenue growth of 16.5% year-over-year, indicating solid performance in its sector.
Insider Buying and Selling at Royalty Pharma plc
Several insiders have sold shares recently. Officer Christopher Hite sold 100,000 shares for about $5.9 million on August 18, 2026, and again on September 22, 2026, for approximately $5.85 million. Officer Marshall J. Urist also sold 4,126 shares at prices around $57.88 and $57.10 on September 28 and October 5, respectively.
Analysts Set New Price Targets
On October 7, 2026, Morgan Stanley maintained an Overweight rating on Royalty Pharma with a price target of $67. On September 8, 2026, TD Cowen also maintained a Buy rating with a target of $68, indicating continued confidence in the stock's potential.
About Royalty Pharma
Royalty Pharma plc specializes in acquiring biopharmaceutical royalties and funding innovation within the industry. The company holds royalties on numerous marketed therapies and development-stage product candidates across various therapeutic areas like oncology and rare diseases, making its performance closely watched in the healthcare sector.
Bottom Line
Investors will be looking ahead to the next earnings report on November 4, 2026, to gauge Royalty Pharma's performance amid recent trading activity. Marathon's recent adjustment in its holdings reflects evolving strategies in a competitive market.
Related Filing Alerts
Source: Marathon Asset Management's 13F filing on $RPRX (Oct 26, 2026). 13F filings show holdings as of the end of the reporting quarter and may not reflect the fund's current position. Written by software, not financial advice. How we make alerts